Phage Consultants signs US deal on Staph blocker

Gdansk, Poland: – Specialist Polish-based CRO Phage Consultants (PC) has signed a collaborative deal with NanoSave Technologies Corp of Cheyenne, Wyoming, to develop a targeted bacteriophage (‘phage) that will be highly effective in treating Staphylococcus (Staph) infections.

The agreement signed between Phage consultants and NanoSave’s Bio Tech division establishes a timeline for the development of Viritron VDX, based on a bacteriophage that will be genetically enhanced to target Staphylococcus infections.

Antibiotic resistance

Staph infection affects millions of patients around the world each year, causing a wide range of ailments ranging from relatively minor skin infections such as boils, to more serious infections of the blood, lungs and heart. Staphylococcus variants are also known as MRSA and MSSA that cause many deaths in hospital. Many of the 40 known strains have become difficult to treat, showing increasing resistance to available antibiotics.

Targeted ‘phage-based treatments have been proven effective in various studies conducted around the world.

Bacteriophage leader

Phage Consultants co-founder and CEO, Dr. Marcin Los, commented: “This is a potentially highly significant development for bacteriophage technology, showing that the bacteriophages that have been recognized since the turn of the 20th century can be part of the solution in combatting the worrying increase in antibiotic resistance worldwide.”

“We are excited to be working with Phage Consultants, a leader in bacteriophage research, and Dr. Los, who is highly recognized as a visionary in the area of Phage research,” commented NanoSave Technologies CEO Steve Lovern.

Two-year timeline

Viritron VDX, which is in the early stages of development, is a genetically modified organism that targets Staph bacteria and destroys them.

The agreement calls for a 22 month R&D timeline, which includes the manufacturing and distribution of the Viritron VDX treatment. NanoSave Technologies will market the treatments to countries where current regulations permit it. The company will seek U.S. and European approvals in the future after accumulating data from its use in various markets.

About Phage Consultants

Bacteriophages (phages) are viruses that infect bacteria. First discovered around 1915, phages play an important role in viral biology, used to elucidate DNA viral reproduction through lytic and lysogenic cycles. They have been used for almost a century as alternatives to antibiotics and can have therapeutic effect against multi-drug-resistant strains of many bacteria.

Based in Poland, Phage Consultants is a contract research and manufacturing organization that specializes in bacteriophage detection and characterization and production. PC have become world leaders in using the power of bacteriophage technology in bioprocess infection and contamination control and assisting companies whose production is based on microbial activities in preventing bacteriophage contamination, along with bacterial, fungal and viral contaminations.

Phage Consultants are also specialists in the field of bacteriophage biology with specific expertise on phage activity in bioprocessing. Its team provides unique assistance to pharmaceutical and biotech companies, offering a range of services from personal training to consulting and process optimization in phage growth limitation. The company also advises and assists clients in the development of new production facilities.

About NanoSave Technologies

Wyoming-based NanoSave Technologies™ (OTC: NNSV) is a global leader in the Nano and BioTechnology arenas. The company was founded in 2012 and is already a world leader in high-performance nano-engineered products. NanoSave N1™, the brand name of the company’s full line of Nano Engineered Super Oils & Lubes, is sold Worldwide and is rapidly gaining market share among auto enthusiasts.

The company is primarily focused on Nano and Bio Technology Research and Development. NanoSave Technologies holds numerous patents across a diverse group of product lines.

These include ViritronVDX™, based on Bacteriophage VDX-10, genetically modified and enhanced to target Staphylococcus aureus (MSSA & MRSA) bacteria. Splicing in a gene sequence that increases the bacteriophage’s ability to replicate faster has altered the DNA of the VDX-10, thereby increasing its numbers and increasing its effectiveness in eliminating Staphylococcus bacteria cells. The invention is a unique genetically modified organism that can be programmed to target various harmful life threatening infectious bacteria as global death rates from antibiotic-resistant infections continue to increase.